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Abstract
Background:  Lumiracoxib is a selective cyclooxygenase-2 inhibitor effective in the treatment of
osteoarthritis (OA) with a superior gastrointestinal (GI) safety profile as compared to traditional non-
steroidal anti-inflammatory drugs (NSAIDs, ibuprofen and naproxen). This safety study compared the GI
tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib
in the treatment of OA. Rofecoxib was withdrawn worldwide due to an associated increased risk of CV
events and lumiracoxib has been withdrawn from Australia, Canada, Europe and a few other countries
following reports of suspected adverse liver reactions.
Methods: This randomised, double-blind study enrolled 309 patients (aged greater than or equal to 50
years) with primary OA across 51 centres in Europe. Patients were randomly allocated to receive either
lumiracoxib 400 mg od (four times the recommended dose in OA) (n = 154) or rofecoxib 25 mg od (n =
155). The study was conducted for 6 weeks and assessments were performed at Weeks 3 and 6. The
primary safety measures were the incidence of predefined GI adverse events (AEs) and peripheral oedema.
The secondary safety measures included effect of treatment on the mean sitting systolic and diastolic blood
pressure (msSBP and msDBP). Tolerability of lumiracoxib 400 mg was assessed by the incidence of AEs.
Results: Lumiracoxib and rofecoxib displayed similar GI safety profiles with no statistically significant
difference in predefined GI AEs between the two groups (43.5% vs. 37.4%, respectively). The incidence and
severity of individual predefined GI AEs was comparable between the two groups. The incidence of
peripheral oedema was low and identical in both the groups (n = 9, 5.8%). Only one patient in the
lumiracoxib group and three patients in the rofecoxib group had a moderate or severe event. At Week 6
there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib
group (p < 0.05). A similar percentage of patients in both groups showed an improvement in target joint
pain and disease activity. The tolerability profile was similar in both the treatment groups.
Conclusion: Lumiracoxib 400 mg od (four times the recommended dose in OA) provided a comparable
GI safety profile to rofecoxib 25 mg od (therapeutic dose). However, lumiracoxib was associated with a
significantly better BP profile as compared to rofecoxib.
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Background
Osteoarthritis (OA) is a common condition that affects
18% women and 10% men (aged > 60 years) worldwide
[1]. Treatment for these patients is aimed at controlling
pain, improving functional abilities and enhancing
health-related quality-of-life [2].
Non-selective non-steroidal anti-inflammatory drugs
(NSAIDs) such as naproxen and ibuprofen are widely
used for pain relief in OA. However, upper gastrointesti-
nal (GI) symptoms such as dyspepsia and more impor-
tantly ulcer complications occur in 15–60% of NSAID
users and frequently necessitate co-therapy with H2 recep-
tor antagonists or proton pump inhibitors [3-6]. In a pro-
spective cohort study, it was observed that 81% of patients
taking NSAIDs and having serious GI complications had
no prior GI symptoms [7] and in a survey in the US
among NSAID users, it was observed that nearly 75% of
those who regularly used NSAIDs did not know about or
were unconcerned about NSAID related GI complications
[8]. GI adverse events (AEs) are the main factors limiting
the use of NSAIDs and represent a significant health bur-
den [6]. Renal impairment, vascular constriction and GI
AEs are attributed to inhibition of cyclooxygenase-1
(COX-1), anti-inflammatory and analgesic effect is attrib-
uted to inhibition of COX-2. Hence, selective COX-2
inhibitors like celecoxib and rofecoxib provide a more
favourable GI safety profile with similar efficacy as com-
pared to non-selective NSAIDs in patients with OA [9,10].
Rofecoxib, however, was withdrawn worldwide on Sep-
tember 30, 2004 due to an increase in the cardiovascular
(CV) risk [11]. Following this withdrawal, concerns have
also been raised regarding CV safety of both selective
COX-2 inhibitors and traditional NSAIDs. These concerns
arose initially for selective COX-2 inhibitors following the
worldwide withdrawal of rofecoxib. Meta-analyses have
since reported an increased risk of CV events with both
traditional NSAIDs and COX-2 inhibitors and both carry
warnings to this effect in their prescribing information
[12-14].
Lumiracoxib is a structurally distinct, selective COX-2
inhibitor for the management of OA and acute pain.
Lumiracoxib is effective in treating acute pain conditions
such as post-operative dental pain [15], acute gout [16],
arthroplasty [17], sprains and strains [18] and in treating
chronic pain associated with OA [19,20].
The 52-week Therapeutic Arthritis Research and Gastroin-
testinal Event Trial (TARGET) in 18 000 patients with OA
investigated the GI, CV and overall safety profile of lumi-
racoxib 400 mg od (four times the recommended dose for
OA) compared to two traditional NSAIDs, naproxen 500
mg bid and ibuprofen 800 mg tid [21,22]. The TARGET
study showed that lumiracoxib was associated with a 79%
decrease in upper GI complications compared to tradi-
tional NSAIDs (non-aspirin population) [21]. The GI ben-
efit with lumiracoxib compared to traditional NSAIDs
occurred within 8 days of treatment [23]. In TARGET
lumiracoxib was also associated with an improved blood
pressure (BP) profile as compared to the traditional
NSAIDs, already after 4 weeks of treatment [24] and the
effect was maintained until 52 weeks [22].
The present short-term safety study assessed the GI tolera-
bility of a 6-week treatment with lumiracoxib 400 mg od
(four times the recommended dose for OA) as compared
to rofecoxib 25 mg od (therapeutic dose) in patients with
OA. In addition, the study also assessed renal effects
including the incidence of peripheral oedema and
changes in BP in the two treatment groups.
Methods
Study design
This study was a 6-week, multicentre, randomised, dou-
ble-blind, double-dummy, active-controlled, parallel-
group, safety study of lumiracoxib 400 mg od (four times
the recommended dose for OA) compared to rofecoxib 25
mg od. The study enrolled subjects with primary OA
across 51 centres in Europe. This study was performed
according to Good Clinical Practice guidelines. Ethics
committee approval from all participating institutions
was obtained in accordance with the Declaration of Hel-
sinki and all patients gave their written informed consent
before enrolment. The study had a 3–7 day wash-out
period, 6-week treatment period and a follow-up by
phone call 2 weeks after the end of study/early termina-
tion.
Study population
Symptomatic patients (aged ≥50 years) with OA as
defined by the American College of Rheumatology criteria
were recruited. The criteria for inclusion were primary OA
for at least 3 months in the hip, hand, knee or spine (cer-
vical or lumbar) and pain in the target joint of at least
moderate intensity (Likert scale). Patients also needed to
be on NSAID or other analgesic therapy or expected to
need NSAID treatment for at least 6 weeks.
The exclusion criteria were secondary OA and/or history/
evidence of significant diseases in the affected joints, evi-
dence of active ulceration or bleeding of the upper GI
tract, upper GI tract malignancies, diseases of the intesti-
nal tract and bleeding diathesis. Patients were excluded if
they had clinically significant hepatic or renal disease, evi-
dence of hepatic, renal or blood coagulation disorders or
anaemia, hypertension, type I diabetes or other significant
medical problems, used systemic steroids, intra-articular
hyaluronic acid injections, H2 receptor antagonists, pro-
ton pump inhibitors, sucralfate or prostaglandin ana-BMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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logues in the past month. Pregnant or lactating women
and women not on acceptable form of contraception were
also excluded.
Study medication and assessments
Patients were randomly allocated in the ratio of 1:1 to
receive either lumiracoxib 400 mg od (four times the rec-
ommended dose for OA) or rofecoxib 25 mg od. Lumira-
coxib (Prexige® Novartis Pharma AG, Basel, Switzerland)
was provided as 2 × 200 mg tablets with matching place-
bos and rofecoxib as 25 mg capsules with matching place-
bos. Patients were asked to take the medication once every
morning at approximately the same time. Compliance
with study drug was defined as patients taking ≥80% of
the full daily dose. To control GI symptoms, patients were
allowed a maximum of eight antacid tablets (calcium car-
bonate 680 mg/magnesium carbonate 80 mg) per day as
rescue medication. Patients received the study medication
for 6 weeks.
Safety assessments
The key primary assessment was incidence of at least one
of the predefined GI AEs: abdominal pain, constipation,
diarrhoea, nausea, vomiting, dyspepsia and dysphagia.
The other primary assessment was incidence of peripheral
oedema: lower limb oedema, upper limb oedema, periph-
eral swelling and peripheral oedema. The secondary safety
assessments were incidence of moderate and severe prede-
fined GI AEs, incidence of each individual predefined GI
AE, discontinuations from study because of any AE or GI
AE and time to discontinuation, mean sitting systolic and
diastolic blood pressure (msSBP and msDBP), and the
number of tablets of antacid rescue medication taken.
Study assessments were performed at baseline, Weeks 3
and 6.
Tolerability was evaluated by recording AEs during the
entire study period. A follow-up phone call 2 weeks after
the end of study was carried out to evaluate serious
adverse events (SAEs) after study drug discontinuation.
Investigators were requested to report all SAE's which
occurred within 4 weeks after last dose of study drug
intake. Vital signs including BP measurements and stand-
ard laboratory tests were performed at baseline, Weeks 3
and 6. ECG recordings were performed at baseline and
Week 6.
Efficacy assessment
Efficacy variables were overall pain intensity in the target
joint and the global assessments of disease activity by
patients and physicians on a 5-point Likert scale at Weeks
3 and 6. For overall pain intensity in the target joint,
patients were classified as improved if endpoint assess-
ment was "none" or improved by at least two grades from
baseline on the Likert scale. For patient's and physician's
global assessment of disease activity, patients were classi-
fied as improved if endpoint assessment was "very good"
or improved by at least two grades from baseline.
Statistical analysis
The categorical efficacy variables were analysed in the
intent-to-treat (ITT) population defined as all randomised
patients who received study medication. A multiple logis-
tic model (PROC LOGISTIC in SAS), which considered
treatment as main effect was used for the analysis. The
treatment contrasts were tested at a two-sided 5% signifi-
cance level and presented as odds ratios (ORs) together
with their 95% confidence intervals (CIs). Missing data
for efficacy variables were imputed using the last-observa-
tion-carried-forward (LOCF) method. The primary safety
endpoints were analysed in the safety population defined
as all patients randomised to treatment, who had been
exposed to study medication. A multiple logistic model,
which took into account country and treatment as the
main effect was used for the analysis. The treatment con-
trasts were tested at a two-sided 5% level of significance
and presented as ORs together with their 95% CIs. If the
estimated incidence rates were less than 5%, or if the
logistic regression model did not converge, Fisher's exact
test was used for the comparisons. Analysis was repeated
in the per-protocol (PP) population defined as a sub-pop-
ulation of the safety population for sensitivity reasons.
Between-treatment comparisons for msSBP and msDBP
were performed by means of analysis of covariance
(ANCOVA). For the ANCOVA models, treatment and
country were taken as fixed effects and the respective base-
line values as covariate. Time to discontinuation from
study due to any AE or GI AE was analysed using life-table
methods. Patient compliance and other categorical safety
endpoints were analysed using a multiple logistic model
at a two-sided 5% significance level and presented as ORs
together with their 95% CIs.
Sample size and power considerations
The determination of the sample size was based on the
key primary safety variable, the incidence of predefined GI
AEs. A two-group continuity corrected chi-squared test
with a two-sided 5% significance level had 80% power to
detect a clinically relevant difference between the treat-
ment groups, assuming 28% in the rofecoxib group and
14% in the lumiracoxib group when the sample size is
146 patients per treatment arm. Three hundred and four
patients (152 each on lumiracoxib and rofecoxib) needed
to be randomised to allow for a 4% dropout rate.
Results
After an initial wash-out period of 3–7 days, a total of 309
patients were randomised to either lumiracoxib 400 mg
od (n = 154) or rofecoxib 25 mg od (n = 155) (Figure 1).
All randomised patients were included in the ITT andBMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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safety populations. At baseline, the treatment groups were
comparable in terms of demographic and baseline charac-
teristics (Table 1). Medical histories indicated that more
patients on lumiracoxib had vascular disorders as com-
pared to rofecoxib (54.5% vs. 46.5%, respectively). His-
tory of cardiac disorders at baseline was more frequent in
lumiracoxib patients (16%) than rofecoxib patients
(11%). In both the groups, a similar percentage (42%) of
patients had previously undergone surgical and medical
procedures. More than 90% of patients in both the treat-
ment groups completed the study. Major protocol viola-
tions resulting in exclusion from the PP population
occurred in 13 patients receiving lumiracoxib and seven
patients receiving rofecoxib.
Primary safety endpoints
There was no statistically significant difference in the over-
all incidence of key primary assessment variables (prede-
fined GI AEs – abdominal pain, constipation, diarrhea,
nausea, vomiting, dyspepsia and dysphagia) between the
treatment groups (OR: 1.31; 95% CI: 0.82, 2.11, p  =
0.258). Predefined GI AEs were reported in 43.5% (n =
67) of patients in lumiracoxib group and 37.4% (n = 58)
of patients in rofecoxib group. Thus, overall both the
study drugs displayed similar GI safety profiles. The inci-
dence of the other primary assessment variable, peripheral
oedema was low in both the treatment groups (n = 9,
5.8%) (Figure 2).
Secondary safety endpoints
There was no statistically significant difference between
lumiracoxib and rofecoxib for the incidence of individual
predefined GI AEs. Minor differences between lumira-
coxib and rofecoxib in the incidence rates for diarrhoea
(11.0% vs. 5.2%), dyspepsia (26.6% vs. 20.6%) and con-
stipation (2.6% vs. 0.6%) were observed, but were not sta-
tistically significant. When the incidence rates of these
predefined GI AEs were analysed based on their severity it
was observed that moderate or severe predefined GI AEs
associated with lumiracoxib and rofecoxib were compara-
ble with the exception of dyspepsia that occurred more
often in the lumiracoxib group (11.0% lumiracoxib vs.
4.5% rofecoxib, p = 0.035, Fisher's exact test [Table 2]).
The rate of moderate-to-severe peripheral oedema was
low in both treatment groups. Only one patient in the
lumiracoxib group (0.6%) versus three patients (1.9%) in
the rofecoxib group had a moderate-to-severe event. This
numerical difference was not statistically significant. After
6 weeks of treatment, a significantly lower msSBP and
msDBP was observed with lumiracoxib as compared to
rofecoxib (least square estimated difference: -3.13 mmHg,
Table 1: Demographic and baseline characteristics (safety population)
Lumiracoxib 400 mg od
(n = 154)
Rofecoxib 25 mg od
(n = 155)
Age (years)† 65.3 ± 8.49 65.5 ± 8.67
Women, n (%) 94 (61.0) 100 (64.5)
BMI (kg/m2)† 29.1 ± 5.21 28.3 ± 4.51
Race
Caucasians, n (%) 154 (100.0) 153 (98.7)
Other 0 (0.0) 2 (1.2)
Disease duration (years)† 7.41 ± 7.058 8.37 ± 8.407
Physician's global assessment of disease activity n (%)
Very good 1 (0.6) 2 (1.3)
Good 3 (1.9) 5 (3.2)
Fair 75 (48.7) 66 (42.6)
Poor 69 (44.8) 76 (49.0)
Very poor 6 (3.9) 6 (3.9)
Patient's global assessment of disease activity n (%)
Very good 1 (0.6) 1 (0.6)
Good 9 (5.8) 6 (3.9)
Fair 51 (33.1) 57 (36.8)
Poor 78 (50.6) 77 (49.7)
Very poor 15 (9.7) 14 (9.0)
Pain intensity assessment n (%)
Moderate 74 (48.1) 74 (47.7)
Severe 67 (43.5) 67 (43.2)
Extreme 13 (8.4) 14 (9.0)
Current smokers, n (%) 24 (15.6) 26 (16.8)
BMI = body mass index; Other = Black/African American and Asian or Pacific islander; SD = standard deviation.
†Mean ± SDBMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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95% CI: – 6.17, -0.10, p = 0.043 for msSBP and -1.73
mmHg, 95% CI: -3.43, – 0.03, for msDBP, p = 0.046 [Fig-
ure 3]). The mean number of antacid tablets taken was the
same in both treatment groups (0.2 tablets/day).
The most frequently reported AEs (by preferred term) dur-
ing this study are listed in Table 3. The incidence of AEs
was comparable between lumiracoxib and rofecoxib. The
most commonly reported AEs by primary system organ
class were GI disorders, infections and infestations, and
musculoskeletal and connective tissue disorders, which
were similar in incidence in both treatment groups. Study-
drug related AEs as suspected by the investigator were
reported in 40.9% of patients in the lumiracoxib group
and 37.4% of patients in the rofecoxib group. As expected
in a study focussing on GI safety, AEs were most com-
monly reported in the GI system. Three rofecoxib-treated
patients experienced AEs that led to temporary interrup-
tion of study medication (Table 4).
Discontinuations due to GI AEs occurred in 4.5% and
2.6% of the patients treated with lumiracoxib and
rofecoxib, respectively (p = 0.359). The mean time to dis-
continuation for patients treated with lumiracoxib as
compared to rofecoxib for any AE (23.3 days vs. 21.7 days,
respectively) and for GI AEs (23.4 days vs. 25.3 days,
respectively) was comparable. A similar proportion of
patients discontinued from the study due to any AE in
both groups (5.2% of lumiracoxib and 4.5% of rofecoxib
patients).
No drug-related SAEs or deaths were reported during the
course of the study. One SAE (vaginal haemorrhage) was
reported in the rofecoxib group.
Patient flow diagram Figure 1
Patient flow diagram. †Patients with multiple occurrences of a major protocol violation (PV) were counted only once in 
that category of PV.BMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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Incidence of peripheral oedema in patients treated with lumiracoxib and rofecoxib (safety population) Figure 2
Incidence of peripheral oedema in patients treated with lumiracoxib and rofecoxib (safety population). The inci-
dence of peripheral oedema at Week 6. Pairwise comparisons tested at the two-sided 5% significance level. p-value computed 
using Fisher's exact test. OA, osteoarthritis.
Table 2: Incidence of moderate or severe predefined GI AEs (safety population)
Predefined GI AEs Lumiracoxib 400 mg od
(n = 154)
n (%)
Rofecoxib 25 mg od
(n = 155)
n (%)
Abdominal pain 6 (3.9) 6 (3.9)
Constipation 1 (0.6) 1 (0.6)
Diarrhoea 4 (2.6) 2 (1.3)
Dyspepsia* 17 (11.0) 7 (4.5)
Dysphagia 1 (0.6) 0 (0.0)
Nausea 3 (1.9) 0 (0.0)
Vomiting 1 (0.6) 1 (0.6)
GI = gastrointestinal; AEs = adverse events
*p = 0.032BMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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Serum chemistry and haematology parameters were in the
normal range at baseline for the majority of patients in
both the treatment groups and remained so at the end of
study. No elevations in alanine amino transferase/aspar-
tate amino transferase > 3 × ULN were observed during
the study.
Efficacy endpoint
An improvement in target joint pain or disease activity
was reported in 30–40% of patients in the lumiracoxib
and rofecoxib groups after 6 weeks of treatment (Table 5).
The differences between the treatment groups were not
statistically significant for any efficacy parameter.
Lumiracoxib shows better blood pressure profile as compared to rofecoxib (safety population) Figure 3
Lumiracoxib shows better blood pressure profile as compared to rofecoxib (safety population). msSBP – Mean 
sitting systolic blood pressure. msDBP – Mean sitting diastolic blood pressure. p-value computed from ANCOVA on mean 
blood pressure at Day 42 with centre, treatment, and baseline blood pressure value. Mean change from baseline at Week 6. 
OA, osteoarthritis.
Table 3: Incidence of most frequent AEs (≥2% for either group) by preferred term (safety population)
Lumiracoxib 400 mg od
(n = 154)
n (%)
Rofecoxib 25 mg od
(n = 155)
n (%)
Dyspepsia 41 (26.6) 33 (21.3)
Abdominal pain NOS 15 (9.7) 10 (6.5)
Diarrhoea NOS 15 (9.7) 7 (4.5)
Nausea 8 (5.2) 8 (5.2)
Abdominal pain upper 4 (2.6) 7 (4.5)
Constipation 4 (2.6) 1 (0.6)
Oedema lower limb 6 (3.9) 7 (4.5)
Fatigue 5 (3.2) 4 (2.6)
Nasopharyngitis 9 (5.8) 9 (5.8)
Influenza 6 (3.9) 6 (3.9)
AEs = adverse events; NOS = not otherwise specifiedBMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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Discussion
In this study, both lumiracoxib and rofecoxib showed
similar efficacy in treating pain associated with OA.
The GI safety profile of lumiracoxib 400 mg od (four
times the recommended dose for OA) was comparable to
rofecoxib 25 mg od over 6 weeks of treatment. The inci-
dence of individual predefined GI AEs and their severity
was also comparable between the treatment groups.
Lumiracoxib is indicated at a dose of 100 mg once daily
for chronic use in OA, and at doses of 200 mg or 400 mg
once daily for short-term use in acute pain indications.
While liver toxicity is a known rare but serious side effect
of all COX-2 inhibitors and traditional NSAIDs [25], there
have been some specific concerns from health authorities
regarding the hepatic safety profile of lumiracoxib. Lumi-
racoxib was withdrawn in Australia in August 2007 fol-
lowing reports of severe liver events occurring
predominantly at doses higher than the recommended
dose of 100 mg od, when taken chronically. The US FDA
issued a non-approvable letter in September 2007, citing
concerns over the hepatic profile of lumiracoxib. This was
followed by withdrawals in Canada, Europe and a few
other countries. Assessment of the benefit to risk profile of
the drug is currently ongoing by a number of health
authorities.
Liver toxicity is a known rare but serious side effect of all
COX-2 inhibitors and traditional NSAIDs and it is not
clear the risk is higher with lumiracoxib than other
NSAIDs.
In this 6-weeks study no elevations in liver enzymes were
observed with lumiracoxib. This is in agreement with the
results from TARGET where the incidence of ALT/AST ele-
vations > 3 × ULN were low with lumiracoxib, compara-
ble to ibuprofen and naproxen and no "Hy's cases" (ALT/
AST > 3 × ULN and total bilirubin > 3 mg/dL), which are
more predictive for severe liver outcome, were observed
during the first 49 days of treatment [26].
Traditional NSAIDs and selective COX-2 inhibitors like
rofecoxib and etoricoxib have been shown to increase BP
Table 4: Incidence of deaths and SAEs (Safety population)
Lumiracoxib 400 mg od
(n = 154)
Rofecoxib 25 mg od
(n = 155)
Patients with serious AEs
Death n (%) 0 (0.0) 0 (0.0)
Non-fatal SAEs n (%) 0 (0.0) 1 (0.6)
Patients with other significant AEs
Pre-specified AEs (GI events or oedema) n (%) 73 (47.4) 64 (41.3)
AEs leading to dose adjustment/interruption n (%) 0 (0.0) 3 (1.9)
Discontinuation due to
Any AEs including SAEs n (%) 8 (5.2) 7 (4.5)
SAEs n (%) 0 (0.0) 0 (0.0)
AEs (non-serious) n (%) 8 (5.2) 7 (4.5)
AEs = adverse events; SAEs = serious adverse events; GI = gastrointestinal
Table 5: Efficacy results in patients treated with lumiracoxib and rofecoxib (ITT population)
Week 3 Week 6
Efficacy measures Lumiracoxib 400 mg od
(n = 154)
Rofecoxib 25 mg od
(n = 155)
Lumiracoxib 400 mg od
(n = 154)
Rofecoxib 25 mg od
(n = 155)
Patient's pain intensity
Improved n (%) 53 (34.4) 50 (32.3) 49 (31.8) 63 (40.6)
Non-improved n (%) 101 (65.6) 105 (67.7) 105 (68.2) 92 (59.4)
Patient's global assessment of disease 
activity
Improved n (%) 49 (31.8) 53 (34.2) 57 (37.0) 65 (41.9)
Non-improved n (%) 105 (68.2) 102 (65.8) 97 (63.0) 90 (58.1)
Physician's global assessment of 
disease activity
Improved n (%) 44 (28.6) 46 (29.7) 51 (33.1) 56 (36.1)
Non-improved n (%) 110 (71.4) 109 (70.3) 103 (66.9) 99 (63.9)BMC Musculoskeletal Disorders 2008, 9:118 http://www.biomedcentral.com/1471-2474/9/118
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in clinical studies [27,28] and in the recent Multinational
Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL)
study, discontinuations due to hypertension were
observed more frequently with etoricoxib compared with
diclofenac [29]. In this study, after 6 weeks of treatment, a
statistically significantly better BP profile was observed
with lumiracoxib as compared to rofecoxib, with an esti-
mated difference of more than 3 mmHg systolic blood
pressure (SBP) in favour of lumiracoxib. Although this
difference was small, reports suggest that increases in SBP
of 1–5 mmHg have been associated with 7100–35 700
additional ischemic heart disease and stroke events in OA
patients over a 1-year period in the USA [30]. These find-
ings are consistent with previous findings where a 2
mmHg decrease in SBP reduced the risk of death due to
ischemic heart disease and stroke by approximately 7%
and 10%, respectively, in middle age [31]. Hence, main-
taining BP control can provide substantial benefits in OA
patients [32].
These results are in agreement with the findings of the 12-
month TARGET outcome study with lumiracoxib, where
lumiracoxib had an improved BP profile compared with
ibuprofen or naproxen [22,24]. The improved BP profile
with lumiracoxib as compared to ibuprofen was also
observed in hypertensive OA patients [33]. In addition,
results from a meta-analysis involving 9 611 patients on
lumiracoxib (100–400 mg od) revealed that lumiracoxib
provided a BP profile (both systolic and diastolic) compa-
rable to placebo [34].
Moreover, in TARGET, the incidence of oedema was low
and lumiracoxib was not associated with any increase in
the incidence of oedema, compared with ibuprofen or
naproxen [35], while in the VIGOR study, the incidence of
oedema was higher in the rofecoxib group as compared to
the naproxen group [36]. The incidence of peripheral
oedema was low and similar in both the groups in this
study. A numerical difference for moderate and severe
peripheral oedemas was also observed in favour of lumi-
racoxib, although it did not reach statistical significance.
The incidence of AEs and discontinuations due to AEs
were comparable between the treatment groups. The most
common AEs suspected by the investigator to be study-
drug related were GI AEs, as expected in a study on GI
safety.
Conclusion
Lumiracoxib 400 mg od (four times the recommended
dose in OA) demonstrated comparable GI safety profile to
rofecoxib 25 mg od (therapeutic dose) in patients with
OA. However, lumiracoxib was associated with a signifi-
cantly better BP profile as compared to rofecoxib.
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blood pressure; CIs: confidence intervals; COX: cyclooxy-
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intent-to-treat; LOCF: last-observation-carried-forward;
MEDAL: Multinational Etoricoxib and Diclofenac Arthri-
tis Long-Term; msDBP: mean sitting diastolic blood pres-
sure; msSBP: mean sitting systolic blood pressure;
NSAIDs: non-steroidal anti-inflammatory drugs; OA:
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vate Practice, Roanne; Dr. M. Gacioch, Private Practice,
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Lichtenvoorde; Dr. W.A. de Backer, Private Practice, Rijsw-
ijk; Dr. C.P. Buiks, Private Practice, Ewijk; Dr. H.F.C.M.
Van Mierlo, General Practice Van Mierlo Rembrandt, van
Rijn Singel 37-c, 2371 RB Roelofarendsveen; Dr. A. Veer-
man, Private Practice, Huizen; Dr. M. Passage, Private
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Switzerland: Dr. med. Hans-Ulrich Rentsch, Rheumatol-
ogie, Poststrasse 25, 9000 St Gallen; Dr. R Theiler, Kan-
tonsspital Aarau, Buchserstrasse/Haus 1, 5001 Aarau; Dr.
med. Hans Schwarz, Rheumatologie Bethesda-Spital, Gel-
lertstrasse 144, 4020 Basel; Dr. med. Michel Pellaton, 2,
ruelle du Peyrou, 2000 Neuchâtel; Dr. Heinz Fahrer,
Lindenhofspital/Rheumatologische Klinik, Salihaus
Bremgartenstrasse 117, 3012 Bern; Dr. Ottmar Gor-
schewsky, Klinik Permanence Bern West, Orthopädie
Bümplizstrasse 83, 3018 Bern; Dr. Thomas Lehmann,
Inselspital/Rheumatologische Klinik Eingang-EG-29/Ein-
gang 14a Freiburgstrasse, 3010 Bern; Dr. Paul Hasler, Felix
Platter Spital, Rheumatologie Burgfelderstr. 101, 4012
Basel; Dr. med. Pierre-Alain Buchard, Rhumatologie FMH
Clinique romande de réadaptation, Avenue Grand
Champsec 90, 1951 Sion; Dr. med. Jean Dudler, Hôspital
Nestlé, CHUV Rhumatologie FMH Avenue Pierre-Decker
5, 1005 Lausanne; Dr. Pierre-André Guerne, HCUG Rhu-
matolgoie, FMH Avenue Beau Séjour 25, 1211 Genève 14;
Dr. med. Daniel Uebelhart, Universitätsspital Zürich Glo-
riastrasse 25, 8091 Zürich; Dr. Urs Moser, Rheumatologie
Mühlegasse 3, 4410 Liestal; Dr. med. Michel Braun, Rhu-
matolgoie FMH Rue Gustave-Amweg 21, 2900 Porrentury
United Kingdom: Dr Alun George, The Staploe Medical
Centre, The Staploe Medical Centre Brewhouse Lane
Soham, CB7 5JD Cambridge; Dr Duncan Burwood,
Bedgrove Surgery, Bedgrove Surgery Brentwood Way,
HP21 7TL Aylesbury; Dr Andrew Cowie, The Porch Beech-
field Road, Corsham, SN13 9 Wiltshire; Dr Robert Mat-
thews, The Spa Surgery, The Spa Surgery 6 Spa Road, SN12
7NS Melksham; Dr Anthony Wright, Hathaway Surgery,
Hathaway Surgery 32 New Road, SN15 1 Chippenham;
Dr Kevin Gruffydd-Jones, Box Surgery, Box Surgery Lon-
don Road, SN13 8NA Box, Corsham, Wiltshire
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